共 44 条
A cost-effectiveness analysis of preimplantation genetic testing for aneuploidy (PGT-A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age
被引:23
|作者:
Lee, Evelyn
[1
]
Costello, Michael F.
[2
]
Botha, Willings C.
[3
]
Illingworth, Peter
[4
]
Chambers, Georgina M.
[5
]
机构:
[1] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW, Australia
[2] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia
[3] Univ New South Wales, Ctr Big Data Res Hlth, Natl Perinatal Epidemiol & Stat, Sydney, NSW, Australia
[4] Univ New South Wales, Sch Womens & Childrens Hlth, Sydney, NSW, Australia
[5] IVF Australia Pty Ltd, Sydney, NSW, Australia
来源:
关键词:
aneuploidy;
assisted reproductive technology;
cost-effectiveness analysis;
cumulative live-birth rate;
preimplantation genetic diagnosis;
D O I:
10.1111/ajo.12988
中图分类号:
R71 [妇产科学];
学科分类号:
100211 ;
摘要:
Background Current evidence suggests that preimplantation genetic testing for aneuploidy (PGT-A) used during assisted reproductive technology improves per-cycle live-birth rates but cumulative live-birth rate (CLBR) was similar to a strategy of morphological assessment (MA) of embryos. No study has assessed the cost-effectiveness of repeated cycles with PGT-A using longitudinal patient-level data. Aim To assess the cost-effectiveness of repeated cycles with PGT-A compared to MA of embryos in older women. Materials and Methods Micro-costing methods were used to value direct resource consumption of 2093 assisted reproductive technology-naive women aged >= 37 years undergoing up to three 'complete assisted reproductive technology cycles' (fresh plus cryopreserved embryos) with either PGT-A or MA in an Australian clinic between 2011 and 2014. Incremental cost-effective ratios were calculated from healthcare and patient perspectives with uncertainty assessed using non-parametric bootstrap methods. Cost-effectiveness acceptability curves were constructed to evaluate the probability of PGT-A being cost-effective over a range of willingness-to-pay thresholds. Results The CLBR and mean healthcare costs per patient were 30.90% and $22 962 for the PGT-A group, and 26.77% and $21 801 for the MA group, yielding an incremental cost-effective ratio of $28 103 for an additional live birth with PGT-A. At a willingness-to-pay threshold of $50 000 and above, there is more than an 80% probability of PGT-A being cost-effective from the healthcare perspective and a 50% likelihood from a patient perspective. Conclusion This is the first study to use real-world patient-level data to assess the cost-effectiveness of PGT-A in older women from the healthcare and patient perspectives. The findings contribute to the ongoing debate on the role of PGT-A in clinical practice.
引用
收藏
页码:573 / 579
页数:7
相关论文